Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: A non-inferiority randomized clinical trial
Số trang: 10
Loại file: pdf
Dung lượng: 2.29 MB
Lượt xem: 11
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Diphereline is a Gonadotropin-Releasing Hormone agonist commonly used in patients with breast cancer. This study aimed to compare the efficacy and safety of one-month and three-month Microrelin injections produced by Homa Pharmed Company with three-month Diphereline injections manufactured by IPSEN, France.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Breast cancer Gonadotropin-releasing hormone agonist Menopausal symptoms Drug disruptionGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 167 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 109 0 0 -
12 trang 87 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 35 0 0
-
11 trang 35 0 0
-
12 trang 33 0 0